OPKO Health, Inc. (TLV: OPK)
Market Cap | 3.78B |
Revenue (ttm) | 2.64B |
Net Income (ttm) | -497.13M |
Shares Out | n/a |
EPS (ttm) | -0.72 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 193,813 |
Open | 582.90 |
Previous Close | 582.90 |
Day's Range | 563.10 - 582.90 |
52-Week Range | 315.00 - 639.80 |
Beta | 1.63 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 27, 2025 |
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers,... [Read more]
Financial Performance
In 2023, OPKO Health's revenue was $863.50 million, a decrease of -14.01% compared to the previous year's $1.00 billion. Losses were -$188.86 million, -42.49% less than in 2022.
Financial numbers in USD Financial StatementsNews
NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo
OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow Company Invited to Present at Special Event Hosted by U.S. Consulate General During the Exp...
NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results
Company Sees Initial Sales Momentum in China for OPKO Health Products as it Prepares for the Launch of its Florida Sunshine Brand of Vitamins and Supplements COCONUT GROVE, Fla. , Nov. 14, 2024 /PRNew...
Opko Health (OPK) Q3 2024 Earnings Call Transcript
OPK earnings call for the period ending September 30, 2024.
OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing ...
NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market COCONUT GR...
OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medi...
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Enhances Labcorp's laboratory services network and expands access to its clinical services BURLINGTON, N.C. and MIAMI , Sept.
OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second ...
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPK...
OPKO Health to Participate in the Jefferies Global Healthcare Conference
MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 a...
OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhoun...
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights i...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial ...
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- L...
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans • Candidate showed similar half-life to standard monoclonal antibo...
OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript
OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from...
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S....
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes
MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate principal ...
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...
BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing
ELMWOOD PARK, N.J. , Nov. 28, 2023 /PRNewswire/ -- BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pion...
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- ...
OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman and Chief Executive Of...